POTOMAC FALLS, Va., April 25, 2013 /PRNewswire/ -- TessArae®, LLC and Kindstar Global, the largest esoteric reference laboratory in China, have signed a collaboration agreement for the development of a pan-ethnic carrier screen for the Chinese population. The assay, which will be run in Kindstar's laboratories in China, employs TessArae's targeted sequencing development platform and proprietary bioanalysis software.
The agreement solidifies a development partnership which allows Kindstar to leverage TessArae's design expertise to create and market its own Laboratory Developed Test (LDT) specific to the Chinese market. TessArae's development platform combines a highly multiplexed amplification strategy with a standard Affymetrix microarray protocol. Results are delivered as genomic sequence, automatically generated and analyzed by TessArae's GeneCipher algorithms.
Kindstar Founder and CEO, Dr. Shiang Huang said in a statement, "TessArae's development platform is a unique and valuable tool that provides Kindstar near immediate access to key markets with clinically appropriate, sequence-driven diagnostics. Kindstar is able to capture revenue faster at less cost by partnering with TessArae in the expansion of our test menu."
Dr. Tom Richards, TessArae President and CEO, commented "TessArae's development platform grants our partners the combined benefits of two worlds: the efficiency and predictability of microarrays with the rich specificity of genetic sequencing. As a result, they can develop market-specific genetics assays much more quickly than alternative approaches. We are excited to partner with Kindstar in bringing their vision of recessive disease testing to the Chinese market."
Kindstar provides esoteric diagnostic testing services to hospitals and physicians in all Chinese provinces, including more than 3,300 hospitals, among them 930 large leading hospitals, so-called tertiary hospitals. It has laboratories in Beijing, Shanghai, and Wuhan. Additional company information can be found at www.kindstarglobal.com
TessArae is privately held by a partnership lead by John W. Marriott III of the Marriott hotel family. TessArae is recognized as the market leader in targeted sequencing applications using a microarray. Since its inception, the company has helped design 15 custom assays for a wide variety of partners, including worldwide government agencies, academic institutions and commercial reference laboratories. TessArae's targeted sequencing platform has been analytically validated. Reference laboratories use the TessArae platform to develop their own custom genetics assays. Additional company information can be found at www.tessarae.com
Financial and other terms of the agreement were not disclosed.
SOURCE TessArae, LLC